In recent years, The Business Research Company’s Biomarkers report highlights a remarkable surge in the biomarkers market size, projecting an upward trajectory from $61.31 billion in 2024 to an estimated $69.54 billion, exhibiting a noteworthy Compound Annual Growth Rate (CAGR) of 13.4%. This growth in the historical period finds its roots in the strides made in genomics and proteomics technologies, the rising prevalence of chronic diseases, a burgeoning focus on personalized medicine, the escalating demand for companion diagnostics, and the broadening applications in drug development.
Forecasts for the biomarkers market indicate an accelerated growth path, anticipating a surge to $117.82 billion by 2028, propelled by a robust CAGR of 14.1%. This trajectory is underpinned by an increasing emphasis on early disease detection and prevention, the expansive role of biomarkers in oncology and immunotherapy, heightened investments in precision medicine initiatives, the ascent of liquid biopsy as a non-invasive detection method, and the growing preference for biomarkers in drug discovery and development. Noteworthy trends in the forecast period encompass the evolution of multi-biomarker panels, the emergence of exosome-based biomarkers, the adoption of point-of-care biomarker testing, the integration of real-world data in biomarker research, and the exploration of microbiome-based biomarkers.
Learn More On The Biomarkers Market:
https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report
The increase in heart diseases is expected to propel the growth of the biomarkers market in the forecasted period. The use of biomarkers for heart disease patients has increased tremendously over the last few years. Currently, the natriuretic peptides are the most used biomarker and help in the diagnosis of patients with heart failure. Biomarkers such as circulating biomarkers with high sensitivity C-reactive protein are used for the diagnosis of heart failure. Heart disease is among leading cause of death for people of most racial and ethnic groups in the United States. The increase in heart diseases will drive the demand for biomarkers. For instance, in August 2022, according to a report published by the American College of Cardiology, a US-based non-profit medical association, In the United States, it is anticipated that all four cardiovascular risk factors will increase between 2025 and 2060. The largest percentage rise is expected in diabetes, with a 39.3% increase to 55 million individuals, followed by dyslipidemia (27.6% to 126 million), hypertension (25.1% to 162 million), and obesity (18.3% to 126 million). The researchers also observed that the most substantial projected increases in cardiovascular disease rates were for stroke (33.8% to 15 million) and heart failure (33.4% to 13 million), followed by ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million). Because of the increase in heart diseases and heart deaths, there will be an increase in growth for the biomarkers.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=6485&type=smp
The biomarkers market covered in this report is segmented –
1) By Technology: Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers
2) By Disease: Neurological Diseases, Cancer, Immunological Diseases, Cardiovascular Diseases, Other Diseases
3) By Type: Biomarker Of Exposure, Biomarker Of Diseases
4) By Audiences: Pharmaceutical Companies, Government And Private Research Institutes, Academic Institutes, Medical Device Manufacturing Companies
5) By Application: Risk Assessment, Development of Molecular Diagnostic, Disease Diagnosis, Drug Discovery And Development, Drug Formulation, Forensic Application, Other Applications (DNA Fingerprinting And Others
Top 5 Major Players:
Prominent players in the biomarker market are strategically embracing partnerships to offer expanded decentralized clinical trials to individuals, businesses, and governments. Strategic partnerships, exemplified by the collaboration between Medidata, a US-based technology company, and Labcorp, a US-based healthcare company, showcase a synergy where each entity leverages its strengths and resources for mutual benefit. In a significant development in September 2021, Medidata partnered with Labcorp, augmenting its decentralized clinical trial (DCT) offerings by integrating medical-grade sensor data in drug, vaccine, and device trials. Through the Medidata Sensor Cloud, Labcorp enhances its DCT capabilities, aiming to expedite and enhance patient outcomes. The collaboration extends to co-developing digital biomarkers across diverse medical devices and therapeutic areas, establishing a comprehensive library for advancing therapeutic research and innovating digital diagnostics. This strategic partnership exemplifies a forward-looking approach that aligns with the evolving landscape of biomarker applications in the healthcare industry.
The biomarkers market report table of contents includes:
1. Executive Summary
2. Biomarkers Market Characteristics
3. Biomarkers Market Trends And Strategies
4. Biomarkers Market – Macro Economic Scenario
5. Global Biomarkers Market Size and Growth
…..
31. Global Biomarkers Market Competitive Benchmarking
32. Global Biomarkers Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Biomarkers Market
34. Biomarkers Market Future Outlook and Potential Analysis
35. Appendix
List Of Tables:
Table 1: Global Historic Market Growth, 2018-2023, $ Billion
Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
Table 3: Global Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Table 4: Global Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Table 5: Global Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
….
Table 76: Enzo Biochem Inc Financial Performance
Table 77: Bio-Rad Laboratories Inc. Financial Performance
Table 78: Merck KGaA Financial Performance
Table 79: PerkinElmer Inc. Financial Performance
Table 80: QIAGEN N.V. Financial Performance
Related Reports:
https://topprnews.com/recycled-plastics-market-trend/
https://topprnews.com/recycled-polyethylene-terephthalate-market-size/
https://topprnews.com/red-wine-market-share/
https://goodprnews.com/recycled-plastics-market-trend/
https://goodprnews.com/recycled-polyethylene-terephthalate-market-size/
https://goodprnews.com/red-wine-market-share/
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
